Eli Lilly and Company (LLY) Stock
NYSELLY has an Alpha Score of 57 out of 100 (moderate), computed on Oct 28, 2026 from 3 of 4 sub-scores. 44 members of Congress disclosed 147 trades in LLY since 2014: 68 purchases and 79 sales, most recently Dan Newhouse (partial sale, Jul 10, 2026). 10 of the hedge funds AlphaScala tracks reported LLY in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $1.13B. Company insiders reported 0 open-market buys and 3 sales on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 44.8 and its net margin 33.5% (key statistics as of Oct 22, 2026).
What is LLY's Alpha Score?
How it works →Alpha Score of 56 reflects moderate overall profile with strong momentum, poor value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 28, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Eli Lilly and Company (LLY)?
Most recent: Dan Newhouse (partial sale, Jul 10, 2026); records start Feb 5, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dan Newhouse R-WA · House | 2026-07-10 | partial sale | $1k – $15k |
| Michael Rulli R-OH · House | 2026-07-01 | sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-06-10 | purchase | $50k – $100k |
| Gil Cisneros D-CA · House | 2026-04-14 | purchase | $1k – $15k |
| Lizzie Fletcher D-TX · House | 2026-04-08 | partial sale | $1k – $15k |
| Byron Donalds R-FL · House | 2026-04-02 | purchase | $1k – $15k |
| Alan Armstrong R-OK · Senate | 2026-03-27 | sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-03-13 | partial sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded LLY, with filing lags →Which hedge funds own LLY?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 945K | $1.13B | +291% |
| D.E. Shaw David Shaw | 497K | $595.59M | -22% |
| Marshall Wace | 335K | $401.38M | -42% |
| Millennium Management Israel Englander | 183K | $219.11M | -34% |
| Bridgewater Associates Ray Dalio | 87K | $104.38M | +23% |
| ARK Invest Cathie Wood | 77K | $92.66M | +509% |
| Renaissance Technologies Jim Simons (founder) | 26K | $31.29M | -64% |
| Soros Fund Management George Soros (founder) | 22K | $26.63M | n/a |
| Duquesne Family Office Stanley Druckenmiller | 12K | $14.85M | NEW |
| Point72 Steve Cohen | 10K | $12.57M | -89% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Eli Lilly and Company insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 17, 26 | Jonsson Patrik | EVP & President, LLY Int'l | SELL | 6.5K | $7.6M |
| Aug 10, 26 | Zakrowski Donald A | SVP, Finance, & CAO | SELL | 2.0K | $2.4M |
| Aug 7, 26 | Hakim Anat | EVP, GC & Secretary | SELL | 5.0K | $6.0M |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are LLY's key statistics?
Key statistics as of Oct 22, 2026
How does LLY's valuation compare with the Healthcare sector?
| Metric | LLY | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 44.8 | 27.1 | 97 |
| Net margin | 33.53% | 5.48% | 139 |
| Return on equity | 92.58% | 6.84% | 158 |
| Dividend yield (payers) | 0.75% | 1.62% | 50 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
What did Eli Lilly and Company's latest SEC filings say?
Latest 2Eli Lilly 10-K Filing Reports Financial Results and Strategic Asset Portfolio Activity for 2025
Eli Lilly and Company filed its 10-K for the fiscal year ended December 31, 2025. The filing details the company's financial position, including its debt structure with various notes maturing between 2026 and 2061. The company maintains significant product concentration in its cardiometabolic, oncology, immunology, and neuroscience segments. Key products highlighted include Mounjaro, Zepbound, Trulicity, Jardiance, Verzenio, and Taltz. The company reports customer concentration risk related to its three largest wholesalers. The filing also outlines recent corporate activity, including investments and acquisitions involving Verve Therapeutics, SiteOne Therapeutics, Scorpion Therapeutics, Morphic Holding, and others. The company continues to manage its portfolio through divestitures, such as the previous sale of the Olanzapine portfolio and Baqsimi. Financial disclosures include fair value measurements for marketable securities and debt instruments.
- ›Reported ongoing financial activity across key product lines including Mounjaro, Zepbound, and Jardiance.
- ›Disclosed customer concentration risk involving the company's three largest wholesalers.
- ›Detailed debt maturity schedule for notes ranging from 2026 to 2061.
- ›Confirmed strategic investments and acquisitions in 2025 including Verve Therapeutics, SiteOne Therapeutics, and Scorpion Therapeutics.
- ›Maintained reporting on divestiture impacts from the sale of the Olanzapine portfolio and Baqsimi.
Eli Lilly Files Form 8-K to Announce Fourth Quarter and Full Year Results
Eli Lilly and Company filed a Form 8-K on February 4, 2026, to formally announce its financial results for the quarter and the full fiscal year ended December 31, 2025. The filing serves as a procedural notification regarding the release of the company's earnings performance. The actual financial data, including revenue, earnings per share, and management commentary, is contained within Exhibit 99.1, which is a press release issued by the company on the same date. Per the filing, the information provided under Item 2.02 is furnished and not deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934. This means the information is not subject to the liabilities of that section and is not incorporated by reference into other registration statements or documents filed under the Securities Act of 1933 or the Exchange Act, unless explicitly stated otherwise by the company in future filings.
- ›Company announced financial results for the quarter and year ended December 31, 2025.
- ›Financial results were provided via an attached press release labeled Exhibit 99.1.
- ›The filing confirms the company's compliance with reporting requirements under the Securities Exchange Act of 1934.
LLY price chart
Powered by TradingViewWhat does Eli Lilly and Company do?
Eli Lilly and Company is a leading pharmaceutical company engaged in the discovery, development, manufacture, and sale of human pharmaceutical products. It focuses on innovative medicines addressing critical health needs in areas such as diabetes, oncology, immunology, neuroscience, obesity, cardiovascular diseases, cancer, and other therapeutic categories including bone muscle joint disorders, endocrine conditions, dermatology, autoimmune diseases, sleep apnea, migraine, and Alzheimer's disease. The company offers treatments like insulins, GLP-1 therapies for diabetes and obesity, oncology drugs, immunologic agents, and neuroscience products. Eli Lilly and Company supports access initiatives through partnerships for technology transfer and API supply to manufacturers in low- and middle-income countries, enhancing availability of insulins and other therapies in regions like Africa and Bangladesh. It maintains a robust research and development pipeline targeting non-communicable diseases, with late-stage projects in diabetes, cardiovascular, and oncology areas. Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly and Company plays a significant role in the global health technology sector by delivering therapies that improve patient outcomes across diverse medical fields.